Cordex Pharma has employed Cato BioVentures to perform regulatory services and oversight of clinical testing of its products.

Under the agreement, a portion of Cato’s compensation for rendered services will be in the form of Cordex equity.

Initially, the collaboration will focus on Cordex’ Phase III trial with ATPace for the treatment of paroxysmal supraventricular tachycardia (PSVT). ATPace is a stable formulation of adenosine 5′-triphosphate administered by intravenous injection for the acute termination of PSVT.

Previous articleStimulate This!
Next articleNew Algorithm Yields Links between Alpha-Synuclein Toxicity and Pathways that Affect Cell Survival